69P - Cisplatin based preoperative chemotherapy regimens for basal-like breast cancer potentially improve prognosis even in patients without pCR: A retro...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Early Stage
Presenter Ayane Yamaguchi
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors A. Yamaguchi1, H. Ishiguro2, M. Torii1, M. Takada1, E. Suzuki1, M. Takeuchi1, F. Sato1, M. Toi1
  • 1Breast Surgery, Kyoto University-Graduate school of medicine, 6068501 - Kyoto/JP
  • 2Department Of Target Therapy Oncology, Kyoto University-Graduate school of medicine, 6068501 - Kyoto/JP

Abstract

Background

The extent of residual disease after preoperative chemotherapy is a strong prognostic factor in triple-negative breast cancer. Cisplatin has been incorporated into many chemotherapy regimens for various tumor types in the curative setting; however, its role in breast cancer has not been well established.

Methods

Fifty-eight previously untreated, stage I–III basal-like breast cancer patients treated with or without cisplatin based preoperative chemotherapy regimens from 2007 to 2015 in the Kyoto University Hospital, were consecutively included in the present analysis. Patient characteristics such as tumor size, nodal status, age, tumor grade, Ki-67 status, and estrogen receptor status were retrospectively acquired. All patients were divided into four groups based on their pCR status (with and without) and the inclusion of cisplatin (with and without) in the treatment regimen. Event-free survival (EFS) was analyzed using the Kaplan–Meier method.

Results

Thirty-six cases were treated with cisplatin-based regimens and 22 were treated without cisplatin. The median follow-up period was 4 years and pCR was achieved in 27.3% and 52.8% of the patients treated with and without cisplatin-based regimens, respectively. All patients who achieved pCR were recurrence-free. In the groups without pCR, the 4-year EFS rates with and without cisplatin were 92.9% and 65.6%, respectively. Multivariate analysis indicated that pCR and the use of cisplatin were significant factors of EFS (Table).rn

Table: 69P Multivariate analysis (Event-free survival)

rnrnrnrnrnrnrnrnrnrnrn
Prognostic factorsHazard ratioP value
Age (>54 years, 50 mm, 0.0010.0417
rn

Conclusions

Despite the relatively small patient cohort, our data indicated that cisplatin based chemotherapy improved EFS even in patients without pCR. Cisplatin based preoperative chemotherapy might confer long-lasting anti-tumor activity, leading to better prognosis even in patients without pCR.

Clinical trial indentification

Legal entity responsible for the study

Kyoto University Medical Ethics Committee

Funding

Grants-in-Aid for Scientific Research

Disclosure

All authors have declared no conflicts of interest.